Key Points
- Capricor Therapeutics CFO Anthony Bergmann sold 24,100 shares on June 25 at an average price of $30.38, totaling about $732,158. After the sale, he held 11,223 shares, a 68.23% reduction in ownership.
- Bergmann also made additional recent sales on June 22, June 24, and May 1, continuing a pattern of insider selling in the stock.
- Capricor shares were trading at $24.08, while analysts remain generally upbeat with a Moderate Buy consensus and an average price target of $53.67, despite the company posting a quarterly earnings miss.
Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) CFO Anthony Bergmann sold 24,100 shares of the company's stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares of the company's stock, valued at $340,954.74. This trade represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Anthony Bergmann also recently made the following trade(s):
- On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $15,000.00.
- On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $12,000.00.
- On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00.
Capricor Therapeutics Price Performance
CAPR stock opened at $24.08 on Wednesday. Capricor Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $40.37. The firm has a 50-day moving average of $29.58 and a 200 day moving average of $28.35. The company has a market cap of $1.39 billion, a P/E ratio of -10.38 and a beta of 0.39.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities research analysts expect that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the company. LADENBURG THALM/SH SH upgraded Capricor Therapeutics to a "strong-buy" rating in a research report on Thursday, June 25th. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the company an "overweight" rating in a research report on Friday, March 13th. HC Wainwright restated a "buy" rating and set a $60.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Piper Sandler reaffirmed an "overweight" rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Finally, B. Riley Financial upped their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $53.67.
View Our Latest Stock Analysis on Capricor Therapeutics
Institutional Investors Weigh In On Capricor Therapeutics
A number of institutional investors have recently modified their holdings of the stock. Glenmede Trust Co. NA increased its holdings in shares of Capricor Therapeutics by 13.2% during the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company's stock valued at $1,104,000 after acquiring an additional 4,240 shares in the last quarter. Bank of America Corp DE boosted its stake in Capricor Therapeutics by 672.0% in the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company's stock worth $12,631,000 after purchasing an additional 361,664 shares in the last quarter. Stempoint Capital LP boosted its stake in Capricor Therapeutics by 110.6% in the 1st quarter. Stempoint Capital LP now owns 37,592 shares of the biotechnology company's stock worth $1,143,000 after purchasing an additional 19,739 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in Capricor Therapeutics during the 1st quarter valued at about $687,000. Finally, Ally Bridge Group NY LLC purchased a new stake in Capricor Therapeutics during the 1st quarter valued at about $3,463,000. 21.68% of the stock is owned by hedge funds and other institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
